An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.
First-in-class firibastat, a selective and specific inhibitor of brain aminopeptidase A, safely reduced BP in hypertensive, overweight patients of multiple ethnic origins.
Analysis of data of six randomized sham-controlled trials of renal sympathetic denervation, shows that RSD gave greater reduction in 24-h ambulatory, daytime ambulatory and office SBP and DBP.
ONTARGET and TRANSCEND data show a non-linear association between mean achieved SBP and DBP and clinical outcomes, and event risk was higher in diabetes vs. no diabetes, across the BP spectrum
ACC 2019 The randomized INFINITY trial showed a significant reduction in accrual of subcortical white matter disease in older people receiving more intensive antihypertensive therapy, but mobility and cognitive function were not improved.
An exploratory analysis of SPRINT data using a machine learning method identified a subgroup of smokers with baseline SBP >144 mmHg who had a higher rate of CV events and acute kidney injury with an SBP treatment target of <120 mmHg vs 140 mmHg.
In the SPYRAL HTN-OFF MED study, RDN lowered HR, particularly in the morning. Patients with HR above the median showed a greater drop in HR and BP than those with lower HR at baseline.
The AHA has published a scientific statement on correct blood pressure measurement to update findings released in the 2005 version.
A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.
Bariatric surgery in obese subjects with hypertension resulted in reduced need for antihypertensive medication with similar ABPM profile and nondipping status, and reduced BP variability and lower number of patients with resistant hypertension compared to medical therapy.
In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.
Bryan Williams, co-chair of the 2018 ESC/ESH Hypertension Guidelines, lists the most important new recommendations. Furthermore, he comments on the discussion on differences between the European and American recommendations.